Russian hypertension guidelines 2024: What’s new in 2024?
Abstract. In 2024, the long-awaited update of the Russian Society of Cardiology and the Ministry of Healthcare of Russia hypertension guidelines was published. While maintaining the same position on the overall strategy for the treatment of hypertension, this document has been substantially revised and supplemented with information in accordance with the results of new studies and meta-analyses published over the past 4 years, as well as the 2023 hypertension guidelines of the European Society of Hypertension. The article provides an overview of the main updates to the hypertension clinical guidelines of the Russian Society of Cardiology in 2024 compared to 2020.Kobalava Zh.D., Troitskaya E.A.
Keywords
arterial hypertension
clinical guidelines
Russian Society of Cardiology
European Society of Hypertension
References
1. Gal D, Thijs B, Glanzel W, Sipido KR. A changing landscape in cardiovascular research publication output. J Am Coll Cardiol. 2018;71(14):1584–89.
PMID: 29622166. https://doi.org/10.1016/j.jacc.2018.01.073
2. Gal D, Glanzel W, Sipido KR. Mapping cross-border collaboration and communication in cardiovascular research from 1992 to 2012. Eur Heart J. 2017;38(16):1249–58.
PMID: 27997881. PMCID: PMC5400048. https://doi.org/10.1093/eurheartj/ehw459
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–80.
PMID: 34450083. PMCID: PMC8446938. https://doi.org/10.1016/S0140-6736(21)01330-1
4. Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389(14):1273–85.
PMID: 37632466. PMCID: PMC10589462. https://doi.org/10.1056/NEJMoa2206916
5. World Health Organization. Global report on hypertension: The race against a silent killer. Geneva, Switzerland: World Health Organization. 2023; 276 pp.
ISBN: 978-92-4-008106-2.
6. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):230–329. (Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. 2024 Clinical practice guidelines for hypertension in adults. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024;29(9):230–329 (In Russ.)).
EDN: GUEWLU. https://doi.org/10.15829/1560-4071-2024-6117
7. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):149–218. (Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;25(3):149–218 (In Russ.)).
EDN: TCRBRB. https://doi.org/10.15829/1560-4071-2020-3-3786
8. Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071.
PMID: 37345492. https://doi.org/10.1097/HJH.0000000000003480
9. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A Report of the American College of Cardiology / American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):1269–324.
PMID: 29133354. https://doi.org/10.1161/HYP.0000000000000066
10. Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025. Online ahead of print.
PMID: 40811516. https://doi.org/10.1161/HYP.0000000000000249
11. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018.
PMID: 39210715. https://doi.org/10.1093/eurheartj/ehae178
12. Бойцов С.А., Погосова Н.В., Аншелес А.А., Бадтиева В.А., Балахонова Т.В., Барбараш О.Л. с соавт. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):119–249. (Boytsov SA, Pogosova NV, Ansheles AA, Badtieva VA, Balakhonova TV, Barbarash OL et al. Cardiovascular prevention 2022. Russian national guidelines. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2023;28(5):119–249 (In Russ.)).
EDN: EUDWYG. https://doi.org/10.15829/1560-4071-2023-5452
13. Charchar FJ, Prestes PR, Mills C, Ching SM, Neupane D, Marques FZ et al. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2024;42(1):23–49.
PMID: 37712135. PMCID: PMC10713007. https://doi.org/10.1097/HJH.0000000000003563
14. Geng Q, Yan R, Wang Z, Hou F. Effects of LCZ696 (sacubitril/valsartan) on blood pressure in patients with hypertension: A meta-analysis of randomized controlled trials. Cardiology. 2020;145(9):589–98.
PMID: 32726791. https://doi.org/10.1159/000507327
15. Li Q, Li L, Wang F, Zhang W, Guo Y, Wang F et al. Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies. Medicine (Baltimore). 2019;98(28):e16093.
PMID: 31305392. PMCID: PMC6641826. https://doi.org/10.1097/MD.0000000000016093
16. Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: The PARAMETER study. Hypertension. 2017;69(3):411–20.
PMID: 28093466. https://doi.org/10.1161/HYPERTENSIONAHA.116.08556
17. Poulter NR, Savopoulos C, Anjum A, Apostolopoulou M, Chapman N, Cross M et al. Randomized crossover trial of the impact of morning or evening dosing of antihypertensive agents on 24-hour ambulatory blood pressure. Hypertension. 2018;72(4):870–73.
PMID: 30354703. https://doi.org/10.1161/HYPERTENSIONAHA.118.11101
18. Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ et al.; TIME Study Group. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): A prospective, randomised, open-label, blinded-endpoint, clinical trial. Lancet. 2022;400(10361):1417–25.
PMID: 36240838. PMCID: PMC9631239. https://doi.org/10.1016/S0140-6736(22)01786-X
19. Agarwal R, Sinha AD, Tu W. Chlorthalidone for resistant hypertension in advanced chronic kidney disease. Circulation. 2022;146(9):718–20.
PMID: 36037270. PMCID: PMC9752356. https://doi.org/10.1161/CIRCULATIONAHA.122.060167
20. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1–S87.
PMID: 33637192. https://doi.org/10.1016/j.kint.2020.11.003
21. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. Erratum in: A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2017;377(25):2506.
PMID: 26551272. PMCID: PMC4689591. https://doi.org/10.1056/NEJMoa1511939
22. Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL et al.; SPRINT Research Group. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28(9):2812–23.
PMID: 28642330. PMCID: PMC5576945. https://doi.org/10.1681/ASN.2017020148
23. Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: Reconciling results from ACCORD BP and SPRINT. J Am Heart Assoc. 2018;7(18):e009326.
PMID: 30371182. PMCID: PMC6222943. https://doi.org/10.1161/JAHA.118.009326
24. Aggarwal R, Petrie B, Bala W, Chiu N. Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients. Hypertension. 2019;73(6):1275–82.
PMID: 31067189. https://doi.org/10.1161/HYPERTENSIONAHA.119.12697
25. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.
PMID: 32970396. https://doi.org/10.1056/NEJMoa2024816
26. Singh AK, Farag YMK, Agarwal R. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(24):2301.
PMID: 37314722. https://doi.org/10.1056/NEJMc2301923
27. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al.; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474–84.
PMID: 35023547. PMCID: PMC8830527. https://doi.org/10.1093/eurheartj/ehab777
28. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29.
PMID: 33264825. https://doi.org/10.1056/NEJMoa2025845
29. Арутюнов Г.П., Драпкина О.М., Кобалава Ж.Д., Конради А.О., Лопатин Ю.М., Недогода С.В. с соавт. Концепция применения комбинированных препаратов с фиксированными дозировками в первичной и вторичной профилактике сердечно-сосудистых заболеваний. Меморандум экспертов Российского кардиологического общества, Российского общества профилактики неинфекционных заболеваний, Российского научного медицинского общества терапевтов, Российской ассоциации эндокринологов, Ассоциации клинических фармакологов, Евразийской ассоциации терапевтов, Российской ассоциации геронтологов и гериатров. Российский кардиологический журнал. 2024;29(9):138–165. (Arutyunov GP, Drapkina OM, Kobalava ZhD, Konradi AO, Lopatin YuM, Nedogoda SV et al. The concept of fixed-dose combination drugs in primary and secondary prevention of cardiovascular disease. Position paper of the Russian Society of Cardiology, the Russian Society for the Prevention of Noncommunicable Diseases, the Russian Scientific Medical Society of Internal Medicine, the Russian Association of Endocrinologists, the Association of Clinical Pharmacologists, the Eurasian Association of Internal Medicine, the Russian Association of Gerontologists and Geriatricians. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024;29(9):138–165 (In Russ.)).
EDN: RVMZQE. https://doi.org/10.15829/1560-4071-2024-6074
About the Authors
Zhanna D. Kobalava, MD, Dr. Sci. (Medicine), professor, corresponding member of RAS, head of the Department of internal medicine with a course in cardiology and functional diagnostics named after academician V.S. Moiseyev, director of the Institute of clinical medicine of the Medical Institute, RUDN University. Address: 117292, Moscow, 61 Vavilova St.E-mail: zkobalava@mail.ru
ORCID: https://orcid.org/0000-0002-5873-1768. Scopus ID: 7004399203. eLibrary SPIN: 9828-5409
Elena A. Troitskaya, MD, PhD (Medicine), associate professor of the Department of internal medicine with a course in cardiology and functional diagnostics named after academician V.S. Moiseyev, director of the Institute of clinical medicine of the Medical Institute, RUDN University. Address: 117292, Moscow, 61 Vavilova St.
E-mail: trelen@yandex.ru
ORCID: https://orcid.org/0000-0003-1756-7583
Similar Articles
